Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Down 1.9% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX): Vertex Pharmaceuticals, a leader in biotechnology, focuses on developing innovative therapies for serious conditions. The stock saw a downturn in the market today.

Why is Vertex Pharmaceuticals Incorporated going down?

VRTX stock is down 1.9% on Jan 13, 2025 15:28

• Vertex Pharmaceuticals (VRTX) encountered a bearish trend attributed to a Death Cross, signaling a downturn as the stock dropped beneath crucial moving averages.
• Clinical trial setbacks and technical sell signals exerted downward pressure on VRTX, resulting in a 15% decrease over the last half-year.
• Despite recent negativity, Vertex Pharmaceuticals has historically surpassed the market, boasting a 20.1% average annual return over 20 years.
• Investor comparisons of VRTX against peers in the Medical Biomedical and Genetics sector, such as Incyte (INCY), potentially influenced the bearish outlook on Vertex Pharmaceuticals today.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

Vertex Pharmaceuticals ( VRTX ) Stock Moves -0.62%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.

https://www.zacks.com/stock/news/2395333/vertex-pharmaceuticals-vrtx-stock-moves--062-what-you-should-know

INCY vs. VRTX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte ( INCY Quick QuoteINCY - ) and Vertex Pharmaceuticals ( VRTX Quick QuoteVRTX - ) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer ...

https://www.zacks.com/stock/news/2395222/incy-vs-vrtx-which-stock-is-the-better-value-option

Pfizer Is 'Too Low To Sell, Let Dividend Do Its Job': Jim Cramer - NVIDIA ( NASDAQ:NVDA ) , Pfizer ( NYSE:PFE )

Pfizer Inc PFE shares are just "too low to sell," according to Jim Cramer, host of CNBC's "Mad Money Lightning Round." Hold the stock and let "the dividend do the job," Cramer advises, preferring to wait for "some good news" on the Seagen acquisition. Pfizer stock is down more than 7% over the ...

https://www.benzinga.com/markets/25/01/42912295/pfizer-is-too-low-to-sell-jim-cramer-nvidia-robotics-exposure

Vertex Grapples With Bearish Chart As Death Cross Emerges - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals' Death Cross signals a bearish trend as shares fall below all critical moving averages. Clinical trial disappointments and technical sell signals pressure VRTX, down 15% over six months. Vertex Pharmaceuticals Inc VRTX is grappling with bearish technical signals as its ...

https://www.benzinga.com/general/biotech/25/01/42856021/vertex-grapples-with-bearish-chart-as-death-cross-emerges

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 11.7% on an annualized basis producing an average annual return of 20.1%. Currently, Vertex Pharmaceuticals has a market capitalization of $105.56 billion.

https://www.benzinga.com/insights/news/25/01/42851189/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-this-much-today

Trending Today

XRP ($XRP) Crypto Forecast: Up 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Up 5.3% Today

Bonk ($BONK) Crypto Forecast: Up 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 6.9% Today

Peanut Squirrel ($PNUT) Crypto Forecast: Up 14.5% Today

Penn National Gaming Inc. ($PENN) Stock Forecast: Up 5.6% Today

SushiSwap ($SUSHI) Crypto Forecast: Up 7.8% Today

Aave ($AAVE) Crypto Forecast: Up 5.7% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 7.1% Today

Ethereum ($ETH) Crypto Forecast: Up 6.5% Today

Vertex Pharmaceuticals Incorporated Price History

18.11.2024 - VRTX Stock was down 2.3%

• Despite a history of positive performance over the past two decades, VRTX encountered a bearish trend today, potentially linked to profit-taking following a period of consistent growth.
• Comparisons with Bristol Myers Squibb (BMY) regarding value could have affected investor sentiment, leading to a sell-off of VRTX shares.
• General market conditions and specific factors within the sector may have contributed to the bearish movement in VRTX today.
• Investors seem to be reassessing their positions in VRTX amidst recent market shifts and the company's future prospects.

15.10.2024 - VRTX Stock was down 5.1%

• Vertex Pharmaceuticals (VRTX) is a biotechnology company focusing on therapies for serious diseases. Today, the market sentiment was bearish.
• The bearish movement in VRTX today might be linked to a comparison between Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX), leading investors to favor GILD as a better value stock option. This shift in focus could have resulted in a sell-off of VRTX shares.

05.10.2024 - VRTX Stock was up 3.6%

• Vertex Pharmaceuticals had a +1% change in its stock price, surpassing the market downturn.
• Positive comments from Jim Cramer about VRTX, emphasizing the company's impactful work, may have influenced investor confidence.
• Expectations for robust Q3 earnings, with a projected EPS of $4.14 and revenues of $2.72 billion, could have bolstered the bullish trend.
• Despite signs of a bearish market, the optimistic outlook from analysts and investors likely overshadowed technical indicators, propelling the stock upwards.

28.07.2024 - VRTX Stock was up 2.4%

• The bullish movement in VRTX stock today could be attributed to several factors:
• The participation of Vertex Pharmaceuticals in upcoming investor conferences may have sparked investor optimism about potential announcements or developments.
• The long-term outperformance of VRTX in the market could have attracted more investors seeking strong returns.
• The bearish positioning of high-rolling investors may have led to a short squeeze scenario, further driving up the stock price as they covered their positions.

19.11.2024 - VRTX Stock was down 17.1%

• The investigation for potential securities fraud could have caused uncertainty and negative sentiment among investors, leading to the bearish movement in VRTX stock.
• The bullish stance taken by wealthy investors might not have been enough to offset the impact of the securities fraud investigation on the stock.
• Despite outperforming the market over the past 20 years, the current investigation news seems to have overshadowed any positive long-term performance, contributing to the bearish movement in VRTX today.

19.11.2024 - VRTX Stock was down 14.5%

• Wealthy investors have taken a bullish stance on VRTX, as indicated by their recent trades in the options market.
• Despite outperforming the stock market over the past 20 years with an impressive annualized return, VRTX experienced a significant decline in its stock price today.
• The positive movement of the stock market today did not translate into gains for VRTX, as it closed lower than the prior day.
• The comparison between VRTX and Bristol Myers Squibb in terms of value may have influenced investor sentiment towards the stock, contributing to its bearish movement.

19.11.2024 - VRTX Stock was down 10.8%

• Vertex Pharmaceuticals reported less-than-promising Phase 2 results for suzetrigine in treating painful lumbosacral radiculopathy, raising doubts about the drug's effectiveness and market potential.
• Concerns arose among investors following an investigation into securities fraud by Block & Leviton, leading to a decrease in confidence and a sell-off of VRTX shares.
• Despite some positive interest from affluent investors, negative news and legal issues may have dominated sentiment surrounding Vertex Pharmaceuticals.
• The stock's weaker performance compared to the market overall and its performance in relation to peers like Bristol Myers Squibb likely contributed to the downward trend.

13.00.2025 - VRTX Stock was down 1.9%

• Vertex Pharmaceuticals (VRTX) encountered a bearish trend attributed to a Death Cross, signaling a downturn as the stock dropped beneath crucial moving averages.
• Clinical trial setbacks and technical sell signals exerted downward pressure on VRTX, resulting in a 15% decrease over the last half-year.
• Despite recent negativity, Vertex Pharmaceuticals has historically surpassed the market, boasting a 20.1% average annual return over 20 years.
• Investor comparisons of VRTX against peers in the Medical Biomedical and Genetics sector, such as Incyte (INCY), potentially influenced the bearish outlook on Vertex Pharmaceuticals today.

05.10.2024 - VRTX Stock was up 5.9%

• The bullish movement in Vertex Pharmaceuticals' stock could be driven by positive sentiment surrounding the upcoming third-quarter earnings report, with Wall Street anticipating robust figures.
• Endorsements of Vertex Pharmaceuticals by market analysts might have contributed to boosting investor confidence in the company's prospects.
• Despite the market facing a decline overall, VRTX demonstrated resilience and potential strength in its underlying fundamentals, leading to notable gains.

17.06.2024 - VRTX Stock was down 2.9%

• A partnership in novel gene editing technology between Orum Therapeutics and Vertex could have raised concerns among investors about potential competition in the market, leading to a bearish sentiment on VRTX.
• Speculation about CRISPR Therapeutics potentially becoming a strong competitor to Vertex Pharmaceuticals may have impacted investor confidence in VRTX, contributing to the bearish movement.
• Despite Vertex exceeding market returns and receiving expanded approval for TRIKAFTA by Health Canada, the overall market sentiment towards the stock today seems to have been influenced more by future competition and industry dynamics rather than recent positive developments.

25.06.2024 - VRTX Stock was up 1.2%

• VRTX stock saw a significant bullish movement despite the overall struggle in the healthcare sector, indicating company-specific factors at play.
• The insider sale of shares by CEO & President Reshma Kewalramani could have initially raised concerns, but the market seemed to overlook this and focus on other positive aspects.
• The mention of potential impact of political shifts on biotech stocks, including VRTX, might have created uncertainty, but investors still showed confidence in the company's growth prospects.
• VRTX's consistent outperformance over the past 5 years could have also contributed to the positive market sentiment surrounding the stock.

02.07.2024 - VRTX Stock was down 2.1%

• The company reported a substantial loss in Q2, surprising many and triggering a bearish market response.
• Despite the setback, Vertex Pharmaceuticals raised its annual revenue forecast due to high demand for its cystic fibrosis treatments, suggesting a positive future outlook.
• The bearish market sentiment following the Q2 loss and missed earnings may have overshadowed the optimistic revenue forecast.
• Concerns about the company's recovery from the Q2 loss could be contributing to today's decline in stock price.